FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291498082> ?p ?o ?g. }

• W4291498082 endingPage "925" @default.
• W4291498082 startingPage "917" @default.
• W4291498082 abstract "Background/aim: Giant cell arteritis (GCA) is a large vessel vasculitis that may cause significant morbidity in the elderly population. We aimed to evaluate presentation characteristics, treatment, and outcome in a cohort of patients with GCA diagnosed and followed in a single center. Materials and methods: A retrospective chart review revealed 84 (41 M/43 F) registered patients diagnosed with GCA between 1990 and 2020. Clinical features at presentation and follow-up, radiographical imaging, temporal artery biopsy (TAB), and laboratory findings were retrieved from digital medical records or hard-copy patient files. Of these, 33 patients- follow-up period was less than 12 months; hence, relapses and treatment outcomes were examined in the remaining 51 (60.5%) patients. Results: A total of 84 patients were included in the cohort. The mean age at diagnosis was 68.4 ± 7.9 years (range: 49-85). At presentation, 60 (71.4%) patients had headache, 22 (26.2%) had symptoms compatible with polymyalgia rheumatica (PMR), and 23 (27.4%) had visual loss. Three (3.6%) patients had solid organ malignancies while two had hematologic malignancies (2.4%) before GCA diagnosis. TAB was obtained in 63 (75%) patients, in 47 of whom (74.6%) the pathological findings were consistent with GCA. A PET/ CT scan has been performed before glucocorticoids (GCs) initiation in 43 (51.2%) patients and of these, 37 (86.0%) revealed uptake consistent with large vessel involvement. The median follow-up time of the 51 patients was 3.7 (IQR: 1.8-6.8) years. GCs were started promptly after the diagnosis. During the follow-up period, 28 (54.9%) patients experienced a relapse. Thirty-nine (78%) patients were under GC treatment, with a mean dosage of 4.8 ± 2.8 g/day at the final visit. At the final visit, 20.3% (17:84) had died whereas 9.8% (5:51) had permanent vision loss. Conclusion: Treatment of GCA is challenging. GCA causes serious morbidities and increased mortality. PET/CT is highly effective in detecting large vessel vasculitis in GCA and could perhaps replace TAB in the future." @default.
• W4291498082 created "2022-08-15" @default.
• W4291498082 creator A5027514672 @default.
• W4291498082 creator A5055146309 @default.
• W4291498082 creator A5063377738 @default.
• W4291498082 creator A5068493778 @default.
• W4291498082 date "2022-01-01" @default.
• W4291498082 modified "2023-09-26" @default.
• W4291498082 title "Presentation characteristics and clinical outcome of patients with giant cell arteritis followed by a single center" @default.
• W4291498082 cites W1554717495 @default.
• W4291498082 cites W1795206698 @default.
• W4291498082 cites W1967524526 @default.
• W4291498082 cites W1970499838 @default.
• W4291498082 cites W1987316799 @default.
• W4291498082 cites W1988645013 @default.
• W4291498082 cites W1989448550 @default.
• W4291498082 cites W1996771385 @default.
• W4291498082 cites W2010838325 @default.
• W4291498082 cites W2021302871 @default.
• W4291498082 cites W2023249120 @default.
• W4291498082 cites W2039117934 @default.
• W4291498082 cites W2044646622 @default.
• W4291498082 cites W2046402806 @default.
• W4291498082 cites W2060888599 @default.
• W4291498082 cites W2095197307 @default.
• W4291498082 cites W2101528090 @default.
• W4291498082 cites W2109207121 @default.
• W4291498082 cites W2113088965 @default.
• W4291498082 cites W2121355246 @default.
• W4291498082 cites W2123598528 @default.
• W4291498082 cites W2126785391 @default.
• W4291498082 cites W2159685763 @default.
• W4291498082 cites W2163352612 @default.
• W4291498082 cites W2170856389 @default.
• W4291498082 cites W2171282186 @default.
• W4291498082 cites W2268527577 @default.
• W4291498082 cites W2324595831 @default.
• W4291498082 cites W2335361706 @default.
• W4291498082 cites W2469918503 @default.
• W4291498082 cites W2512444844 @default.
• W4291498082 cites W2531581712 @default.
• W4291498082 cites W2613121504 @default.
• W4291498082 cites W2736723784 @default.
• W4291498082 cites W2737436316 @default.
• W4291498082 cites W2753478281 @default.
• W4291498082 cites W2789829771 @default.
• W4291498082 cites W2792199135 @default.
• W4291498082 cites W2947955483 @default.
• W4291498082 cites W2953806781 @default.
• W4291498082 cites W2997386784 @default.
• W4291498082 cites W3044972175 @default.
• W4291498082 cites W3147024200 @default.
• W4291498082 cites W61351317 @default.
• W4291498082 cites W66494512 @default.
• W4291498082 cites W683957 @default.
• W4291498082 doi "https://doi.org/10.55730/1300-0144.5391" @default.
• W4291498082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34565134" @default.
• W4291498082 hasPublicationYear "2022" @default.
• W4291498082 type Work @default.
• W4291498082 citedByCount "1" @default.
• W4291498082 countsByYear W42914980822023 @default.
• W4291498082 crossrefType "journal-article" @default.
• W4291498082 hasAuthorship W4291498082A5027514672 @default.
• W4291498082 hasAuthorship W4291498082A5055146309 @default.
• W4291498082 hasAuthorship W4291498082A5063377738 @default.
• W4291498082 hasAuthorship W4291498082A5068493778 @default.
• W4291498082 hasBestOaLocation W42914980821 @default.
• W4291498082 hasConcept C126322002 @default.
• W4291498082 hasConcept C141071460 @default.
• W4291498082 hasConcept C167135981 @default.
• W4291498082 hasConcept C195910791 @default.
• W4291498082 hasConcept C2775934546 @default.
• W4291498082 hasConcept C2776015282 @default.
• W4291498082 hasConcept C2776712624 @default.
• W4291498082 hasConcept C2777601897 @default.
• W4291498082 hasConcept C2779134260 @default.
• W4291498082 hasConcept C2780073493 @default.
• W4291498082 hasConcept C2780079024 @default.
• W4291498082 hasConcept C2781343717 @default.
• W4291498082 hasConcept C2908647359 @default.
• W4291498082 hasConcept C71924100 @default.
• W4291498082 hasConcept C72563966 @default.
• W4291498082 hasConcept C99454951 @default.
• W4291498082 hasConceptScore W4291498082C126322002 @default.
• W4291498082 hasConceptScore W4291498082C141071460 @default.
• W4291498082 hasConceptScore W4291498082C167135981 @default.
• W4291498082 hasConceptScore W4291498082C195910791 @default.
• W4291498082 hasConceptScore W4291498082C2775934546 @default.
• W4291498082 hasConceptScore W4291498082C2776015282 @default.
• W4291498082 hasConceptScore W4291498082C2776712624 @default.
• W4291498082 hasConceptScore W4291498082C2777601897 @default.
• W4291498082 hasConceptScore W4291498082C2779134260 @default.
• W4291498082 hasConceptScore W4291498082C2780073493 @default.
• W4291498082 hasConceptScore W4291498082C2780079024 @default.
• W4291498082 hasConceptScore W4291498082C2781343717 @default.
• W4291498082 hasConceptScore W4291498082C2908647359 @default.
• W4291498082 hasConceptScore W4291498082C71924100 @default.
• W4291498082 hasConceptScore W4291498082C72563966 @default.

• next